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Introduction
•

•

•
•

•
•

Definition- Acute inflammatory lung injury
associated with increased pulmonary vascular
permeability, increased lung weight, and loss
of aerated lung tissue (Bellani et al., 2016).
Initially defined in 1967 in the Observational
Lung Study in The Lancet (Pham & Rubenfeld,
2017).
10-15% of patients admitted to ICUs are
diagnosed with ARDS (Siegel, 2020).
Incidence of ARDS in the United States are
64.2 to 78.9 cases per 100,000 person years
(Diamond et al., 2020).
Incidence increases with patient age and
increased severity (Diamond et al., 2020).
Mortality increases with severity 27% with
mild, 32% with moderate, and 45% with
severed, overall ARDS has a mortality of 43%
(Diamond et al., 2020).

Signs and Symptoms
•

•

•
•

•

•

Berlin Definition: Respiratory failure within
one week of a known insult, not entirely by
cardiac function or volume overload, with
bilateral opacities seen on chest radiography
or chest CT scan (Matthay et al., 2019).
Severity is defined by the PaO2/FiO2 ratio.
Mild ARDS P/F between 201-300 mmHg,
Moderate ARDS P/F between 101-200 mmHg,
Severe ARDS P/F ratio <101 mmHg (Matthay
et al., 2019).
Dyspnea, hypoxemia, rapid onset and
worsening shortness of breath.
Central and peripheral cyanosis, tachycardia,
altered mental status, decreased oxygen
saturations, rales on lung auscultation (Mayo
Clinic, 2018).
Risk Factors include advanced age, female
gender, smoking, alcohol use, aortic vascular
surgery, cardiovascular surgery, and
traumatic brain injury (Diamond et al., 2020).
Genetic component to ARDS (Sweeney &
McAuley, 2016).

Chest X-ray of ARDS patient (Diamond et al., 2020).

Implication for Nursing Care

Underlying Pathophysiology
Three phases of ARDS exudate, proliferation, fibrotic.
Initial lung injury can be caused by pneumonia, nonpulmonary sepsis, aspiration, or major trauma (Matthay
et al., 2019).

Exudate (Inflammatory) Phase
Occurs within the first 72 hours after initial lung
injury. Initial injury causes diffuse alveolar damage. In
response to the damage proinflammatory cytokines (IL8, TNF-α) are released. Cytokines bring neutrophils to
the lungs. Neutrophils activate and release toxic
mediators (reactive oxygen species and nitric oxide).
Toxic mediators damage endothelium and alveolar
epithelium (McCance & Huether, 2018). Capillary
endothelium damage causes proteins to escape the
vascular space. The oncotic gradient is lost allowing fluid
to leak into the interstitium, backing up the lymphatic
system. Increased interstitial fluid along with damage to
the alveolar epithelium causes the air space to fill with
fluid and cellular debris. Platelet and compliment system
are activated causing microvascular microthrombus
formations damaging the lung epithelium. Pulmonary
vasoconstriction occurs causes pulmonary hypertension
(Siegel, 2020). Impaired type 2 alveolar cells production
related to bronchioles fluid overload and collapse. Type 2
alveolar cells unable to produce surfactant increasing
alveolar collapse. Overall decreased lung compliance,
increased work of breathing, decreased ventilation of
alveoli, and hypercapnia (McCance & Huether, 2018).

Proliferative Phase

Conservative fluid management, with the use of
diuretics, after initial resuscitation of shock was
found to improve outcomes (Matthay et al., 2019).

Occurs around one to three weeks
after the initial injury. Start of healing
of the lungs. First the pulmonary
edema begins to resolve. Fibroblasts,
myofibroblasts and type 2
pneumocytes start to proliferate.
With the proliferation of type 2
pneumocytes surfactant production is
restored. Type 1 pneumocytes
proliferate also, regenerating the cell
epithelium. (McCance & Huether,
2018). This phase overlaps with the
final phase.

Medications

Fibrotic Phase
Occurs two to three week after the
initial injury. During this time cells
remodel and fibrosis occurs Fibrosis
causes damage to alveoli, respiratory
bronchioles and the interstitium. Fibrosis
causes a decreasing in the residual
capacity of the lungs, creating severe
right to left shunting and respiratory
failure. Also can cause increased
pulmonary hypertension. This phase
accounts for long term damage to the
lungs (McCance & Huether, 2018).

The Significance of
Pathophysiology
The chemical
mediator released during
ARDS causes systemic
effects triggering SIRS
and can eventually lead
to multi-system organ
failure and death
(McCance & Huether,
2018). Most patients do
not die from ARDS but
from the complications
caused to other systems.
Short term complications
include blood clots,
collapsed lungs,
infections and scarring.
Long term complication
include breathing
problem , depression,
memory and cognitive
problems, and muscle
weakness (Mayo Clinic,
2018).
Alveolar damage causes by ARDS (Matthay et al., 2019)

Fluid Management

Pathophysiology and
management of ARDS
(Sweeney & McAuley, 2016)
There is no cure for ARDS, but treatment goals are supportive care to reduce
shunting, increase oxygen delivery, decrease oxygen consumption, and avoid further injury
(Diamond et al., 2020).

Oxygenation

In mild ARDS delayed intubation decreases mortality. In mild ARDS bipap/cpap or
heated high flow oxygen are the preferred oxygenation method (Matthay et al., 2019).
Intubated ARDS patients require smaller tidal volumes because of the non-uniformity of
aerations and decreasing overdistention. Determining the correct tidal volume is patient
specific. One method uses the driving pressure (plateau pressure – PEEP) to determine tidal
volume (Matthay et al., 2019). The ARMA study found using 6ml per kg of tidal volume with
a plateau pressure less than 30, decreased mortality by 8.8% and lead to more vent free
days (Sweeney & McAuley, 2016).
Additional treatment includes increasing the positive end-expiratory pressure (PEEP).
Researchers have found by using higher PEEP patients maintain better oxygenation and
alveolar recruitment (Matthay et al., 2019). A meta-analysis of PEEP found increased levels
of PEEP lowered hospital mortality and had less requirements of mechanical ventilation by
day 28 (Sweeney & McAuley, 2016).
In ARDS patients ARDSnet protocol is used to wean patients from the ventilator by
correlating the FIO2 and PEEP requirements (Diamond et al., 2020).
Finally ARDS requires different ventilation modes to better oxygenate the lungs. ARDS
patients may require changing the inspiratory-to –expiratory ratio or even creating an
inverse ratio. In adults the preferred vent mode is Airway Pressure Release Ventilation
(APRV). APRV provides increased oxygenation but has no benefit on mortality (Diamond et
al., 2020).

Pronation

Another treatment of ARDS patients is placing them in a prone position. The prone
position provides a more uniform distribution of lung stress and strain, improving
ventilation and lung/chest wall mechanisms. The PROSEVA study found pronation
decreased 28- and 90-day mortality, increased ventilator free days, and decreased time to
extubation (Koulouras et al., 2016). Pronation benefits about 50-70% of patients if started
within the first week and kept prone for at least eight hours a day for consecutive days.
(Diamond et al., 2020).

Neuromuscular blockade agents (NMBA) are
used to increase ventilator compliance. They are
current best practice and have been shown to
improve 90-day survival and increase time off the
ventilator (Diamond et al., 2020). A recent study by
Petal Clinical Trials Networks (2019) found no
mortality difference comparing the use of NMBA to
patients using light sedation. The new research
could change current practice, but current practice is
supportive of NMBA.
Inhaled pulmonary vasodilators have selective
vasodilation of the pulmonary circulation providing
increased ventilation-perfusion matching and
increased oxygenation (Matthay et al., 2019).
Methyl-prednisone is used in the treatment of
ARDS but does not show any benefits in comparative
studies. Steroids have been found to help resolve
shock and respiratory failure but increase
neuromuscular weakness. Patients started on
steroids later in the course of the illness had
increased mortality rates (Matthay et al., 2019)
No other medications have proven beneficial in
the treatment and management of ARDS (Sweeney
& McAuley, 2016).

ECMO
Veno-venous extracorporeal membrane
oxygenation (ECMO) has proven beneficial with
severe ARDS patients started within the first week
with no organ failure (Matthay et al., 2019).
Extracorporeal carbon dioxide removal removes CO2
from the venous blood and allows the use of low
tidal volumes without the resulting acidosis
(Matthay et al., 2019). Unfortunately ECMO is a
specialized procedure and few hospitals have the
resources or technology to provide.

Conclusion
ARDS is the result of an initial lung injury causing
respiratory failure and can lead to multi-system
organ failure. Research shows that ARDS is
underrecognized causing delays in treatment
initiation resulting in increased patient mortality.
Early recognition and treatment of ARDS provides
better patient outcomes (Bellani et al., 2016).
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